# Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

> **NCT00245154** · PHASE2,PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 296 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** cediranib maleate
- **DRUG:** paclitaxel
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00245154
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-03
- **Primary completion:** 2008-07-04
- **Final completion:** 2013-01-10
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245154, "Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00245154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*